Rigel Pharmaceuticals Files 8-K

TL;DR

Rigel Pharma filed a standard 8-K, mostly exhibits. Nothing major to see here.

AI Summary

On June 25, 2024, Rigel Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's financial statements and exhibits, indicating a routine disclosure rather than a significant event. No specific financial figures or new business developments were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates Rigel Pharmaceuticals is making routine disclosures to the SEC, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — The filing appears to be a routine disclosure of financial statements and exhibits, with no immediate indication of significant new risks or events.

Key Players & Entities

• RIGEL PHARMACEUTICALS, INC. (company) — Registrant
• June 25, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 611 Gateway Boulevard, Suite 900 (address) — Principal executive offices
• South San Francisco, CA 94080 (address) — Principal executive offices
• ( 650 ) 624-1100 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — h Registered Common Stock, par value $0.001 per share RIGL The Nasdaq Stock Mar

Filing Documents

• tm2417992d1_8k.htm (8-K) — 26KB
• tm2417992d1_ex99-1.htm (EX-99.1) — 11KB
• tm2417992d1_ex99-1img001.jpg (GRAPHIC) — 12KB
• 0001104659-24-074574.txt ( ) — 228KB
• rigl-20240625.xsd (EX-101.SCH) — 3KB
• rigl-20240625_lab.xml (EX-101.LAB) — 33KB
• rigl-20240625_pre.xml (EX-101.PRE) — 22KB
• tm2417992d1_8k_htm.xml (XML) — 4KB

01

Item 8.01. Other Events. On June 25, 2024, Rigel Pharmaceuticals, Inc., a Delaware corporation (the " Company "), issued a press release announcing that its board of directors has approved a one-for-10 reverse stock split (the " Reverse Stock Split ") of the Company's common stock, par value $0.001. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference into this Item 8.01. The Reverse Stock Split is expected to become effective on June 27, 2024 as of 12:01 a.m. Eastern Time (the " Effective Time "), with shares to begin trading on a split-adjusted basis at market open on June 27, 2024. In connection with the Reverse Stock Split, every 10 shares of the Company's common stock issued and outstanding as of the Effective Time will be automatically converted into one share of the Company's common stock. The Company's stockholders will be entitled to receive the cash value equal to the fraction to which the stockholder would otherwise be entitled, multiplied by the closing price of the Common Stock, as reported by Nasdaq, on the last trading day prior to the effective date of the Reverse Stock Split. As a result of the Reverse Stock Split, proportionate adjustments will be made to the number of shares of the Company's common stock underlying the Company's outstanding equity awards and the number of shares issuable under the Company's equity incentive plans and other existing agreements, as well as the exercise or conversion price, as applicable.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release, dated June 25, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 25, 2024 RIGEL PHARMACEUTICALS, INC. By: /s/ Raymond J. Furey Raymond J. Furey Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR